RASAL2 Plays Inconsistent Roles in Different Cancers

RAS protein activator like 2 (RASAL2) belongs to the RAS GTPase-activating protein family and plays an important role in several cancers, including ovarian cancer, nasopharyngeal carcinoma, malignant astrocytoma, renal cell carcinoma, bladder cancer, colorectal cancer, liver cancer, triple-negative breast cancer, lung adenocarcinoma, and pancreatic ductal adenocarcinoma. Traditionally, RASAL2 has been regarded as a tumor suppressor but recent studies have found that it is an oncogene in specific types of cancer, such as colorectal cancer, liver cancer, triple-negative breast cancer, triple-negative/estrogen receptor-negative breast cancer. In this review, we summarize the latest findings regarding RASAL2 in cancers, which may be important and useful in clinical practice. We discussed the specific functions and mechanisms of RASAL2 in different kinds of cancer cells (including its inhibition of invasion, metastasis and angiogenesis and its opposite effects), which may provide new directions for cancer research and treatments. RASAL2 exhibits different relationship with clinical cancer stage, histological grade, prognosis and overall survival in different kinds of tumor. RASAL2 is a potential prognostic factor and a new therapeutic target for diagnosis and treatment.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

In this study, we show that LOC389641 is involved in PTC, which suggests that it may be a target for TC therapies. PMID: 32940082 [PubMed - in process]
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research
Conclusion: STAT6 may act as a prognostic biomarker and provide useful information for immunotherapy in thyroid carcinoma. PMID: 32940081 [PubMed - in process]
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research
Conclusion: The results suggest that the regulation of miR-505/HNRNPM may be a novel strategy to improve the targeted therapy of HCC. PMID: 32940078 [PubMed - in process]
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research
Authors: Moll SA, Wiertz IA, Vorselaars AD, Zanen P, Ruven HJ, van Moorsel CH, Grutters JC Abstract Aim: Cancer antigen 15-3 (CA 15-3) is a baseline biomarker in idiopathic pulmonary fibrosis (IPF), but its value during follow-up is unknown. Materials and methods: Associations between serum CA 15-3 and pulmonary function tests during 1-year follow-up were evaluated by a mixed model in 132 IPF treated with pirfenidone or nintedanib. Results: Increased baseline (median: 56 kU/l) and follow-up CA 15-3 levels were inversely associated with forced vital capacity and diffusing capacity of the lung for carbon monoxid...
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research
Biomarkers for immune checkpoint inhibitors in non-small-cell lung cancer. Biomark Med. 2020 Jul;14(11):929-932 Authors: Fuschillo S, Battiloro C, Rocco D, D Gravara L, Motta A, Maniscalco M PMID: 32940076 [PubMed - in process]
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research
Conclusion: Metabolite biomarker candidates for PC are useful for detecting high-risk IPMN, which can progress to PC. PMID: 32940075 [PubMed - in process]
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research
Conclusion: This study indicated that approximately a third of the CRC patients are diagnosed with EMAST, hereupon EMAST as a prognostic and predictive biomarker should be more studied clinically. PMID: 32940074 [PubMed - in process]
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research
This article aims to review current advances in revealing relationship between tumors and abnormal N-glycosylation and discuss leading-edge applications of N-glycosylation in developing novel tumor biomarkers. PMID: 32940073 [PubMed - in process]
Source: Future Medicine: Biomarkers in Medicine - Category: Internal Medicine Tags: Biomark Med Source Type: research
PMID: 32938341 [PubMed - in process]
Source: Current Topics in Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Top Med Chem Source Type: research
This study clear implicates computational and experimental studies involving Lys104 of KRASG12D and GEF and provides a target for the analysis of future treatments.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
More News: Adenocarcinoma | Astrocytoma | Bladder Cancer | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Colorectal Cancer | Hepatocellular Carcinoma | Kidney Cancer | Liver | Liver Cancer | Nasopharyngeal Cancer | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Renal Cell Carcinoma | Study | Urology & Nephrology